How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/metastatic-nonsmall-cell-lung-cancer-with-no-sensitising-egfr-mutation-or-alk-translocation.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Metastatic nonsmall cell lung cancer with no sensitising EGFR mutation or ALK translocation — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Metastatic nonsmall cell lung cancer with no sensitising EGFR mutation or ALK translocation (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Metastatic nonsmall cell lung cancer with no sensitising EGFR mutation or ALK translocation, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Yervoy	Yervoy	Bristol-Myers Squibb		Cytotoxic T-lymphocyte protein 4
Yervoy	ipilimumab	Bristol-Myers Squibb	CTLA-4-directed Blocking Antibody	Cytotoxic T-lymphocyte protein 4		2011-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Bristol-Myers Squibb · 2 drugs in Metastatic nonsmall cell lung cancer with no sensitising EGFR mutation or ALK translocation

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Metastatic nonsmall cell lung cancer with no sensitising EGFR mutation or ALK translocation:

Cite this brief

Drug Landscape (2026). Metastatic nonsmall cell lung cancer with no sensitising EGFR mutation or ALK translocation — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/metastatic-nonsmall-cell-lung-cancer-with-no-sensitising-egfr-mutation-or-alk-translocation. Accessed 2026-06-10.

Metastatic nonsmall cell lung cancer with no sensitising EGFR mutation or ALK translocation full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing